Generic Pharmaceutical Market in Kenya and Nigeria, Forecast to 2022

Generic Pharmaceutical Market in Kenya and Nigeria, Forecast to 2022

Greater Regulatory Control and a Shift of Focus Away from Costly and Branded Drugs will Increase Generic Drugs’ Market Share

RELEASE DATE
10-Apr-2019
REGION
Africa
Research Code: PA37-01-00-00-00
SKU: HC03159-AF-MR_23014
$3,000.00
In stock
SKU
HC03159-AF-MR_23014
$3,000.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The African continent grapples with a huge burden of communicable diseases, particularly HIV/AIDS, tuberculosis, and malaria. With African governments facing major health financing challenges, a significant proportion of these disease areas are financed by global aid organizations that are also helping in poverty eradication in the continent. Parallelly, with each passing year, the incidence of non-communicable diseases has also been on the rise, along with the rising incomes of the African people. With rising incomes, there is greater indulgence in Westernised diets and unhealthy lifestyles that involve high alcohol intake and tobacco smoking.

The pharmaceutical market in Africa has had to keep up with these trends, providing the necessary medicines to combat the various diseases affecting people in African countries. While branded medicines have dominated the pharmaceutical market in the past decades, the current situation seems to favour the generic alternatives instead, as these achieve similar therapeutic outcomes. Taking into consideration the major financing challenges mentioned above, price becomes a key negotiating factor, resulting in governments focusing on acquiring the cheapest drugs in the global market.

Moreover, the supply chains and distribution channels in countries such as Kenya and Nigeria cater to more than 240 million people collectively. These channels are often overwhelmed, particularly with the additional challenges posed by an underdeveloped regulatory environment. This has led to a stronger focus on developing local pharmaceutical capabilities amongst both private and public sectors to cut down on imports that have historically been subject to exchange rate fluctuations. Interest in local manufacturing is growing, and governments are slowly transforming the regulatory environment to create a more conducive operating environment for pharmaceutical investors.

Research Scope

The study covers the following pharmaceutical therapeutic segments: anti-infective, cancer, cardiovascular, central nervous system, diabetes, and respiratory.


Research Highlights

  • Market overview and projections for the generic pharmaceutical market (2017–2022)
  • Pharmaceutical supply chain analysis and discussion for Kenya and Nigeria
  • Revenue forecast for the generic pharmaceutical market in each country
  • Key trends, key participants, participant strategies, competitive environment analysis, and growth opportunities
  • Strategic recommendations and future outlook of the generic pharmaceutical market

Key Issues Addressed

  • What is the generic pharmaceutical market size in Kenya and Nigeria?
  • How is the pharmaceutical supply chain structured in these two countries?
  • Who are the key generic pharmaceutical suppliers in Kenya and Nigeria?
  • Who are the key distributors in the Kenyan and Nigerian generic pharmaceutical markets?
  • What are the key growth opportunities in the Kenyan and Nigerian generic pharmaceutical markets?

Table of Contents

Key Findings

Scope

Segmentation

Revenue Share by Therapeutic Segment

Key Questions this Study will Answer

Key Market Drivers

Drivers Explained

Drivers Explained (continued)

Key Market Restraints

Restraints Explained

Restraints Explained (continued)

Healthcare Overview—Kenya

Total Pharmaceutical Market Overview—Kenya

Generic Pharmaceutical Market Overview—Kenya

Generic vs. Branded Segmentation—Kenya

Revenue Forecast—Kenya

Revenue Forecast Discussion—Kenya

Key Generic Pharmaceutical Products—Kenya

Total Pharmaceutical Supply Chain—Kenya

Generic Pharmaceutical Supply Chain—Kenya

Supply Chain Analysis—Kenya

Competitive Environment—Kenya

Competitive Environment Assessment—Kenya

Healthcare Overview—Nigeria

Total Pharmaceutical Market Overview—Nigeria

Generic Pharmaceutical Market Overview—Nigeria

Generic vs. Branded Segmentation—Nigeria

Revenue Forecast—Nigeria

Revenue Forecast Discussion—Nigeria

Total Pharmaceutical Supply Chain—Nigeria

Generic Pharmaceutical Supply Chain—Nigeria

Supply Chain Analysis—Nigeria

Competitive Environment—Nigeria

Competitive Environment Assessment—Nigeria

Growth Opportunity 1—Public-Private Partnerships

Growth Opportunity 2—Regulatory Reform

Growth Opportunity 3—API Manufacturing

Growth Opportunity 4—Vaccine Manufacturing

Growth Opportunity 5—Research and Development

Strategic Imperatives for Pharmaceutical Companies

The Last Word—3 Big Predictions

Legal Disclaimer

List of Exhibits

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
The African continent grapples with a huge burden of communicable diseases, particularly HIV/AIDS, tuberculosis, and malaria. With African governments facing major health financing challenges, a significant proportion of these disease areas are financed by global aid organizations that are also helping in poverty eradication in the continent. Parallelly, with each passing year, the incidence of non-communicable diseases has also been on the rise, along with the rising incomes of the African people. With rising incomes, there is greater indulgence in Westernised diets and unhealthy lifestyles that involve high alcohol intake and tobacco smoking. The pharmaceutical market in Africa has had to keep up with these trends, providing the necessary medicines to combat the various diseases affecting people in African countries. While branded medicines have dominated the pharmaceutical market in the past decades, the current situation seems to favour the generic alternatives instead, as these achieve similar therapeutic outcomes. Taking into consideration the major financing challenges mentioned above, price becomes a key negotiating factor, resulting in governments focusing on acquiring the cheapest drugs in the global market. Moreover, the supply chains and distribution channels in countries such as Kenya and Nigeria cater to more than 240 million people collectively. These channels are often overwhelmed, particularly with the additional challenges posed by an underdeveloped regulatory environment. This has led to a stronger focus on developing local pharmaceutical capabilities amongst both private and public sectors to cut down on imports that have historically been subject to exchange rate fluctuations. Interest in local manufacturing is growing, and governments are slowly transforming the regulatory environment to create a more conducive operating environment for pharmaceutical investors.--BEGIN PROMO--

Research Scope

The study covers the f

More Information
No Index No
Podcast No
Author Takudzwa Musiyarira
Industries Healthcare
WIP Number PA37-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9825-B1,99CB-B1,9611-B1